Provided by Tiger Trade Technology Pte. Ltd.

NeuroPace Inc.

13.76
-0.1800-1.29%
Post-market: 13.760.00000.00%19:30 EDT
Volume:120.88K
Turnover:1.67M
Market Cap:469.13M
PE:-24.18
High:14.06
Open:14.02
Low:13.73
Close:13.94
52wk High:19.60
52wk Low:9.22
Shares:34.09M
Float Shares:23.28M
Volume Ratio:0.74
T/O Rate:0.52%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5690
EPS(LYR):-0.6560
ROE:-103.27%
ROA:-7.47%
PB:39.48
PE(LYR):-20.98

Loading ...

Neuropace - to Submit Submission Issue Request and Amend Pma Supplement

THOMSON REUTERS
·
Jul 29

Neuropace Receives FDA Guidance on Pma Supplement for Indication Expansion into Idiopathic Generalized Epilepsy

THOMSON REUTERS
·
Jul 29

Neuropace - FDA Requests Additional Clinical Evidence from Nautilus Trial for Pma Supplement

THOMSON REUTERS
·
Jul 29

Neuropace Inc : Mizuho Initiates Coverage with Outperform Rating; Target Price $22

THOMSON REUTERS
·
Jul 23

NeuroPace Shareholders Approve Directors and Auditor at Meeting

TIPRANKS
·
Jun 09

NeuroPace shareholders elect directors at annual meeting

Reuters
·
Jun 09

NeuroPace attends ASSFN meeting, spotlights expanding role of responsive neuromodulation in epilepsy care

Reuters
·
May 29

NeuroPace wins FDA approval for ECoG Assistant AI epilepsy feature

Reuters
·
May 29

Neuropace Announces FDA Approval of Ecog Assistant™, Advancing AI-Driven Epilepsy Care

THOMSON REUTERS
·
May 29

Analysts Conflicted on These Healthcare Names: NeoGenomics (NEO) and NeuroPace (NPCE)

TIPRANKS
·
May 27

NeuroPace price target raised to $20 from $19 at H.C. Wainwright

TIPRANKS
·
May 16

NeuroPace Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 16

NeuroPace Earnings Call Highlights RNS Growth Momentum

TIPRANKS
·
May 14

NeuroPace (NPCE) Receives a Buy from Lake Street

TIPRANKS
·
May 13

NeuroPace: Buy Rating Reiterated on Raised Guidance, Differentiated RNS Platform, and Attractive $20 Price Target Versus High-Growth Med-Tech Peers

TIPRANKS
·
May 13

Neuropace Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

NeuroPace Q1 Loss Narrows, Revenue Declines

MT Newswires Live
·
May 13

NeuroPace Q1 revenue rises 20%, beats estimates, raises 2026 outlook

Reuters
·
May 13

NeuroPace Q1 EPS $(0.20) Beats $(0.23) Estimate, Sales $22.068M Beat $21.644M Estimate

Benzinga Earnings
·
May 13

NeuroPace Q1 net loss widens to $6.7 million; revenue rises 20.1% to $22 million

Reuters
·
May 13